Used primarily as an antimalarial agent, it is highly effective against Plasmodium falciparum, including multidrug-resistant strains. It acts rapidly during the blood stage of the parasite’s life cycle, reducing parasite load quickly. Due to its short half-life, it is commonly combined with longer-acting antimalarial drugs in artemisinin-based combination therapies (ACTs), which are recommended by the WHO as first-line treatment for uncomplicated malaria. It is also being investigated for potential antiviral, anti-inflammatory, and anticancer properties, particularly in studies involving tumor cell inhibition and immune modulation. Its ability to generate reactive oxygen species contributes to both its antimalarial and possible antitumor effects.